Where am I: Product information > Efficacy > Study 1

Study 1 - Nickel et al 2008¹

This real-life multicentre clinical practice study demonstrated that Uracyst is effective in relieving the symptoms of PBS/IC and reducing symptom and bother scores, thus demonstrating an improvement in patients’ quality of life.

Fifty-three patients with long-standing, moderately severe PBS/IC received Uracyst once a week for 6 weeks, then once a month for 4 months. Every patient completed the study and received a total of ten instillations.

Results

For the primary outcome at 10 weeks (after 6 weekly treatments), the responder rate* was 47.2% and demonstrated clinical significance (see figure 1). Secondary efficacy endpoints assessed the percentage of responders after 24 weeks (10 treatments) and symptom and bother scores (see figures 1, 2 and 3).

*A responder was indicated by a marked or moderate improvement on a seven-point patient Global Response Assessment (GRA) scale.

Response Rate with Uracyst¹

View Fig.1

Uracyst significantly improves patient quality of life¹

View Fig.2

Secondary endpoint measures also included differences from baseline in O’Leary-Sant Symptom/Problem Index scores over the course of the treatment, until the end of the study (24 weeks). O’Leary-Sant Symptom Score decreased by a mean of five points (p<0.001 vs. baseline) or 37% reduction after 6 instillations (6.2 points, 43% after 10 instillations; p<0.001); O’Leary-Sant Bother Score decreased by a mean of 4.3 points (p<0.001 vs. baseline) or 35% reduction after 6 instillations (5.7 points, 44% after 10 instillations; p<0.001).

Uracyst significantly reduces the symptoms of PBS/IC¹

View Fig.3
Pain, urgency, and frequency scores (measured on a visual analogue scale) were also measured over the course of the treatment period. Significant reductions in pain, urgency and frequency (p<0.001) scores were reported after 6 and 10 instillations. Reductions in each symptom score compared to baseline are demonstrated on the graph above.

∧ Back to top